Heidelberg Pharma AG
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1999-01-01
- Employees
- 105
- Market Cap
- -
- Website
- http://heidelberg-pharma.com
Clinical Trials
11
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Heidelberg Pharma AG
- Target Recruit Count
- 78
- Registration Number
- NCT04879043
- Locations
- 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Mount Sinai, The Tisch Cancer Instutute, New York, New York, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours
- First Posted Date
- 2013-05-21
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Heidelberg Pharma AG
- Target Recruit Count
- 13
- Registration Number
- NCT01859351
- Locations
- 🇬🇧
Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
🇬🇧Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
🇬🇧Guy's and St Thomas' Foundation Trust, Guy's Hospital, London, United Kingdom
REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
- Conditions
- Kidney CancerRenal Cell Carcinoma
- Interventions
- First Posted Date
- 2013-01-07
- Last Posted Date
- 2017-12-22
- Lead Sponsor
- Heidelberg Pharma AG
- Registration Number
- NCT01762592
- Locations
- 🇺🇸
David Geffen School of Medicine, UCLA, Los Angeles, California, United States
🇺🇸H. Lee Moffitt Cancer Center & Research Center, Tampa, Florida, United States
🇺🇸Lahey Clinic, Burlington, Massachusetts, United States
Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours
- First Posted Date
- 2012-04-19
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Heidelberg Pharma AG
- Target Recruit Count
- 41
- Registration Number
- NCT01581060
- Locations
- 🇬🇧
Queen's University Belfast Cancer Centre, Belfast, United Kingdom
🇬🇧Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
🇬🇧St James' Institute of Oncology, Leeds, United Kingdom
Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2014-02-28
- Lead Sponsor
- Heidelberg Pharma AG
- Target Recruit Count
- 132
- Registration Number
- NCT00615940
- Locations
- 🇺🇸
Montefiore Medical Center Weiler Division Department, New York, New York, United States
🇺🇸Universitys Hospital Case Medical Center, Cleveland, Ohio, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
- Prev
- 1
- 2
- Next
News
RedHill Biopharma Secures Key Chinese Patent for COVID-19 Treatment RHB-107
RedHill Biopharma has received allowance from China's intellectual property authority for a composition-of-matter patent covering RHB-107, strengthening its position in the $3 billion COVID-19 therapeutics market.